DLL3-guided therapies in small-cell lung cancer: from antibody-drug conjugate to precision immunotherapy and radioimmunotherapy
- Standort
-
Deutsche Nationalbibliothek Frankfurt am Main
- Umfang
-
1 Online-Ressource.
- Sprache
-
Englisch
- Erschienen in
-
DLL3-guided therapies in small-cell lung cancer: from antibody-drug conjugate to precision immunotherapy and radioimmunotherapy ; volume:23 ; number:1 ; day:10 ; month:5 ; year:2024 ; pages:1-5 ; date:12.2024
Molecular cancer ; 23, Heft 1 (10.5.2024), 1-5, 12.2024
- Urheber
-
Su, Po-Lan
Chakravarthy, Karthik
Furuya, Naoki
Brownstein, Jeremy
Yu, Jianhua
Long, Meixiao
Carbone, David
Li, Zihai
He, Kai
- Beteiligte Personen und Organisationen
-
SpringerLink (Online service)
- DOI
-
10.1186/s12943-024-02012-z
- URN
-
urn:nbn:de:101:1-2407220950221.748191604602
- Rechteinformation
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Letzte Aktualisierung
-
14.08.2025, 11:03 MESZ
Datenpartner
Dieses Objekt wird bereitgestellt von:
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Beteiligte
- Su, Po-Lan
- Chakravarthy, Karthik
- Furuya, Naoki
- Brownstein, Jeremy
- Yu, Jianhua
- Long, Meixiao
- Carbone, David
- Li, Zihai
- He, Kai
- SpringerLink (Online service)
Ähnliche Objekte (12)
HER3 targeting with an antibody‐drug conjugate bypasses resistance to anti‐HER2 therapies
The First FDA-Approved Antibody-Drug Conjugate
Placenta-specific1 (PLAC1) is a potential target for antibody-drug conjugate-based prostate cancer immunotherapy
Rovalpituzumab Tesirine: A Novel DLL3-Targeting Antibody–Drug Conjugate
Antibody–Drug Conjugate Revolution in Breast Cancer: The Road Ahead
An Antibody‐Drug Conjugate for Multiple Myeloma Prepared by Multi‐Arm Linkers
Correction to: Antibody–Drug Conjugate Revolution in Breast Cancer: The Road Ahead
Leveraging PET to image folate receptor α therapy of an antibody-drug conjugate
Fcγ Receptor-Dependent Internalization and Off-Target Cytotoxicity of Antibody-Drug Conjugate Aggregates
Developing an Antibody–Drug Conjugate Approach to Selective Inhibition of an Extracellular Protein
Design considerations of an IL13Rα2 antibody–drug conjugate for diffuse intrinsic pontine glioma
An amino acid transporter subunit as an antibody–drug conjugate target in colorectal cancer
HER3 targeting with an antibody‐drug conjugate bypasses resistance to anti‐HER2 therapies
The First FDA-Approved Antibody-Drug Conjugate
Placenta-specific1 (PLAC1) is a potential target for antibody-drug conjugate-based prostate cancer immunotherapy
Rovalpituzumab Tesirine: A Novel DLL3-Targeting Antibody–Drug Conjugate
Antibody–Drug Conjugate Revolution in Breast Cancer: The Road Ahead
An Antibody‐Drug Conjugate for Multiple Myeloma Prepared by Multi‐Arm Linkers
Correction to: Antibody–Drug Conjugate Revolution in Breast Cancer: The Road Ahead
Leveraging PET to image folate receptor α therapy of an antibody-drug conjugate
Fcγ Receptor-Dependent Internalization and Off-Target Cytotoxicity of Antibody-Drug Conjugate Aggregates
Developing an Antibody–Drug Conjugate Approach to Selective Inhibition of an Extracellular Protein
Design considerations of an IL13Rα2 antibody–drug conjugate for diffuse intrinsic pontine glioma
An amino acid transporter subunit as an antibody–drug conjugate target in colorectal cancer
HER3 targeting with an antibody‐drug conjugate bypasses resistance to anti‐HER2 therapies
The First FDA-Approved Antibody-Drug Conjugate
Placenta-specific1 (PLAC1) is a potential target for antibody-drug conjugate-based prostate cancer immunotherapy
Rovalpituzumab Tesirine: A Novel DLL3-Targeting Antibody–Drug Conjugate
Antibody–Drug Conjugate Revolution in Breast Cancer: The Road Ahead
An Antibody‐Drug Conjugate for Multiple Myeloma Prepared by Multi‐Arm Linkers
Correction to: Antibody–Drug Conjugate Revolution in Breast Cancer: The Road Ahead
Leveraging PET to image folate receptor α therapy of an antibody-drug conjugate
Fcγ Receptor-Dependent Internalization and Off-Target Cytotoxicity of Antibody-Drug Conjugate Aggregates
Developing an Antibody–Drug Conjugate Approach to Selective Inhibition of an Extracellular Protein
Design considerations of an IL13Rα2 antibody–drug conjugate for diffuse intrinsic pontine glioma